VA Augmentation and Switching Treatments for Improving Depression Outcomes
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The overall purpose is to determine research based 'next-steps' for outpatients with major
depressive disorder who have not had satisfactory outcomes to standard 'first-step'
treatments. The primary objective is to compare the acute (up to 12 weeks) treatment
effectiveness of augmenting an antidepressant with aripiprazole or with bupropion-slow
release (SR) vs. switching treatment to bupropion-SR monotherapy on symptom remission in
Veterans with Major Depressive Disorder (MDD) who have not achieved optimal response after an
adequate trial on antidepressant (a selective serotonin reuptake inhibitor [SSRI] or
serotonin and norepinephrine reuptake inhibitor [SNRI] or mirtazapine) monotherapy. The
secondary objectives are to compare the acute (up to 12 weeks) and long term (up to 36 weeks)
efficacy, safety, effects on functioning, suicidality, quality of life, anxiety and other
associated symptoms, costs and cost-effectiveness of each of the three treatments.